Stay updated with breaking news from விலே கல்வி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The social and economic cost of eating disorders in the United States 3-Mar-2021 12:40 PM EST, by Wiley Economic costs (2019 US dollars) of eating disorders by age group and gender. Newswise The impact of eating disorders in the United States was nearly $400 billion in 2018-19 when considering both economic costs and reduced wellbeing, according to a study published in the Investigators estimated that the total economic cost associated with eating disorders in 2018-19 was $64.7billion, equivalent to $11,808 per affected person, and the substantial reduction in wellbeing associated with eating disorders was valued at $326.5 billion. Our study lays bare the devastating economic impact that eating disorders have in the United States, a country where the majority of people affected suffer alone and never receive appropriate treatment because of barriers to healthcare and lack of training for healthcare provider ....
Date Time Share Study Shows Opioid Use among U.S. Patients with Knee Osteoarthritis Costs 14 Billion Dollars in Societal Costs Although guidelines do not recommend use of opioids to manage pain for individuals with knee osteoarthritis, a recent study published early online in Arthritis Care & Research, an official journal of the American College of Rheumatology and the Association of Rheumatology Professionals, estimates that 858,000 Americans use opioids such as tramadol and oxycodone for their knee pain, equating to $14 billion in lifetime opioid-related societal costs, or nearly $0.5 billion annually. A team led by Elena Losina, PhD, Robert W. Lovett Professor of Orthopedic Surgery, of Brigham and Women’s Hospital, used a computer simulation to estimate the annual and lifetime contribution of opioids to knee osteoarthritis-related costs. The researchers show the direct medical cost of knee osteoarthritis treatment including opioids totals $7.45 billion or 53 ....
Date Time Acid Reflux Disease May Increase Risk of Cancers of Larynx and Esophagus Results from a large prospective study indicate that gastroesophageal reflux disease (GERD), which also causes heartburn symptoms, is linked with higher risks of various cancers of the larynx (or voice box) and esophagus. The study is published early online in CANCER, a peer-reviewed journal of the American Cancer Society. GERD, a gastrointestinal disorder that affects approximately 20 percent of U.S. adults, occurs when stomach acid flows back into the esophagus, where it can cause tissue damage. Research indicates that this damage may put patients at risk of developing a type of cancer called esophageal adenocarcinoma. ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. AMMO, Inc. Releases Transcript of February 16th Earnings Call and Follow-Up Q&A AMMO, Inc.February 18, 2021 GMT SCOTTSDALE, Ariz., Feb. 18, 2021 (GLOBE NEWSWIRE) AMMO, Inc. (Nasdaq: POWW ) (“AMMO” or the “Company”), a premier American ammunition and munition components manufacturer and technology leader, is pleased to provide a link to the transcript and summary excerpts of the Q&A session from the Company’s 2021 Third Quarter Earnings call held on February 16, 2021. Replay: ADVERTISEMENT Fiscal 2022 is positioned to be transformative in AMMO’s opinion, with revenue and earnings per share increasing significantly as the Company continues to deploy resources to solidify Fiscal 2021’s trajectory. ....
Press release content from PR Newswire. The AP news staff was not involved in its creation. Therapeutic Solutions International Appoints Internationally Renowned Tumor Immunologist Dr. Boris Minev to its Scientific Advisory Board February 16, 2021 GMT ELK CITY, Idaho, Feb. 16, 2021 /PRNewswire/ Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today appointment of Dr. Boris Minev to the Scientific Advisory Board of the Company. Dr. Minev joins other internationally renowned tumor immunologists including Dr. Francesco Marincola, Dr. Santosh Kesari, and Dr. Feng Lin. Dr. Boris Minev is currently the President of Medical and Scientific Affairs at Calidi Biotherapeutics, Inc. in San Diego, CA. Dr. Minev has a stellar track record of successes in the area of cancer immunotherapy, being a developer of Melacine® the first tumor vaccine to obtain regulatory approval. He held a position as the Director of Immunotherapy and Translational Oncology a ....